R&D How innovative trial approaches are advancing rare disease r... Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.
R&D Novel study designs for rare diseases Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.
R&D External control arms and debunking real-world data myths For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies to patients faster, say COTA
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.